Overview
CRISPR-Cas9 is a molecular tool derived from bacterial immune systems that allows scientists to edit DNA with unprecedented precision. Since its adaptation for genome editing in 2012 by Jennifer Doudna and Emmanuelle Charpentier, CRISPR has transformed biology, earning the pair the 2020 Nobel Prize in Chemistry.
How It Works
The system uses a guide RNA molecule to direct the Cas9 enzyme to a specific DNA sequence. Once there, Cas9 cuts both strands of the double helix. The cell's natural repair machinery then fixes the break—either disabling the gene (NHEJ) or inserting a new sequence (HDR). Newer variants like base editors and prime editors offer even finer control.
Medical Applications
Clinical trials are underway for sickle cell disease, beta-thalassemia, certain cancers, and hereditary blindness. In 2023, the UK and US approved Casgevy, the first CRISPR-based therapy, for sickle cell disease. Gene therapies targeting HIV, Alzheimer's risk genes, and heart disease are in early stages.
Ethical Concerns
The 2018 case of He Jiankui, who created CRISPR-edited babies in China, ignited global debate about germline editing—changes that pass to future generations. Most scientific bodies support somatic (non-heritable) editing but call for moratoriums on germline modifications until safety and ethical frameworks are established.